Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea by 源��룄�쁺 et al.
 Annals of Surgical Treatment and Research 275
pISSN 2288-6575 • eISSN 2288-6796
https://doi.org/10.4174/astr.2019.96.6.275
Annals of Surgical Treatment and Research
ORIGINAL ARTICLE
Staged partial hepatectomy versus transarterial 
chemoembolization for the treatment of spontaneous 
hepatocellular carcinoma rupture: a multicenter analysis 
in Korea
Hyung Soon Lee1, Gi Hong Choi2, Jin Sub Choi2, Kwang-Hyub Han3, Sang Hoon Ahn3, Do Young Kim3,  
Jun Yong Park3, Seung Up Kim3, Sung Hoon Kim4, Dong Sup Yoon5, Jae Keun Kim5, Jong Won Choi6,  
Soon Sun Kim7, Hana Park8
1Department of Surgery, National Health Insurance Service Ilsan Hospital, Goyang, Korea 
2Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
3Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
4Department of Surgery, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea
5Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
6Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea
7Department of Internal Medicine, Ajou University Medical Center, Ajou University School of Medicine, Suwon, Korea
8Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea
Received December 21, 2018, Revised March 16, 2019, 
Accepted April 1, 2019
Corresponding Author: Jin Sub Choi
Department of Surgery, Severance Hospital, Yonsei University College of 
Medicine, 50-1 Yonsei-ro, Seodaemoon-gu, Seoul 03722, Korea
Tel: +82-2-2228-2122, Fax: +82-2-313-8289
E-mail: choi5491@yuhs.ac
ORCID code:  https://orcid.org/0000-0002-6467-6494
Copyright ⓒ 2019, the Korean Surgical Society
cc  Annals of Surgical Treatment and Research is an Open Access Journal. All 
articles are distributed under the terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which 
permits unrestricted non-commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: The aim of this study was to identify the prognostic factors and compare the long-term outcomes of staged 
hepatectomy and transarterial chemoembolization (TACE) for patients with spontaneous rupture of hepatocellular 
carcinoma (HCC).
Methods: This study is a multicenter, retrospective analysis of patients with newly diagnosed ruptured HCC. To compare 
overall survival between staged hepatectomy group and TACE alone group, we performed propensity score-matching to 
adjust for significant differences in patient characteristics. To identify prognostic factors, the clinical characteristics at the 
time of diagnosis of tumor rupture were investigated using Cox-regression analysis.
Results: From 2000 to 2014, 172 consecutive patients with newly diagnosed ruptured HCC were treated in 6 Korean 
centers. One hundred seventeen patients with Child-Pugh class A disease were identified; of which 112 were initially 
treated with transcatheter arterial embolization (TAE) for hemostasis and five underwent emergency surgery for bleeder 
ligation. Of the 112 patients treated with TAE, 44 underwent staged hepatectomy, 61 received TACE alone, and 7 received 
conservative treatment after TAE. Those that underwent staged hepatectomy had significantly higher overall survival 
than those that underwent TACE alone before matching (P < 0.001) and after propensity score-matching (P = 0.006). 
Multivariate analysis showed that type of treatment, presence of portal vein thrombosis, pretreatment transfusion >1,200 
mL, and tumor size >5 cm were associated with poor overall survival.
Conclusion: Staged hepatectomy may offer better long-term survival than TACE alone for spontaneous rupture of HCC. 
Staged hepatectomy should be considered in spontaneous rupture of HCC with resectable tumor and preserved liver 
function.
[Ann Surg Treat Res 2019;96(6):275-282]
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INTRODUCTION
Spontaneous rupture of hepatocellular carcinoma (HCC), 
a life-threatening complication with a high mortality rate 
(25%–75%), develops in about 2%–12% of patients with HCC [1-3]. 
Previous studies have reported that the prognosis of ruptured 
HCC is very poor, and that spontaneous tumor rupture occurs 
at an advanced tumor stage in patients with a poor liver 
functional reserve [4]. And the current TNM staging systems 
still classify ruptured HCC as T4 [5].
According to recent studies, the classification of all ruptured 
HCC as T4 may not be reliable [2,3,6]. A nationwide survey in 
Japan demonstrated that tumor rupture itself had a negative 
impact on patient survival [2]; however, the negative impact of 
spontaneous tumor rupture only corresponded to an additional 
0.5 to 2.0 TNM stages on the baseline tumor status, which was 
not strong enough to cancel the effects of other tumor-related 
parameters. Additionally, Chan et al. [3] recently reported that 
HCC rupture appeared to increase the T-stage by one level 
for otherwise T1–2 tumors but had no additional prognostic 
impact on T3 tumors or on tumors >10 cm. Thus, classifying 
all ruptured HCC as T4 may not reliably predict long-term 
outcomes, and the significance of tumor rupture in the tumor 
staging system has been so far been only provisional.
Actually, spontaneous ruptured HCCs are heterogeneous, 
with different liver functional statuses and various tumor 
stages, excluding the rupture factor. Thus, although the patients 
had a recent rupture episode, the treatment is crucial for the 
long-term outcomes, allowing for liver functional reserve 
and resectable tumor status. Resection and transarterial 
chemoembolization (TACE) are widely performed for ruptured 
HCC. Although many previous studies reported favorable long-
term outcomes of staged partial hepatectomy, the optimal 
treatment for ruptured HCC remains under debate [3,6,7]. 
Additionally, it remains uncertain whether TACE actually has 
therapeutic benefits for patients with spontaneous rupture of 
HCC [8-10].
Thus, we aimed to identify the prognostic factors and to 
compare the long-term outcomes of staged hepatectomy and 
TACE for patients with spontaneous ruptured HCC.
METHODS
Patient selection
We retrospectively collected data of patients managed for 
spontaneous rupture of HCC during the period from January 
2000 to December 2014 in 6 Korean centers. The diagnosis of 
spontaneous rupture of HCC was confirmed using dynamic 
contrast-enhanced abdominal CT [11]. The medical records were 
retrospectively reviewed after approval by the Institutional 
Review Boards of Yonsei University College of Medicine and the 
requirement for informed consent was waived (4-2014-0912).
Review of patient data
We analyzed clinical data including age, sex, hepatitis B 
virus surface antigen positivity, Child-Pugh class, shock on 
presentation, administration of blood transfusions, serum 
α-FP and des-gamma-carboxy prothrombin (DCP), hemoglobin, 
platelet count, creatinine, aspartate aminotransferase, alanine 
aminotransferase, total bilirubin, international normalized 
ratio, number of hospitalization days, type of treatment, time 
from HCC rupture until surgery, type of surgery, complications 
of surgery, recurrence pattern after surgery, duration of follow-
up, and outcome. Only the last measurements of α-FP and 
DCP prior to treatment were considered. Major hepatectomy 
was defined as the resection of ≥3 anatomical segments, as 
described by Couinaud. Imaging features were determined by 
pretreatment radiologic findings including tumor multiplicity, 
size, and location and presence of portal vein thrombosis.
Treatment and patient follow-up
In hemodynamically unstable patients with continuous 
hemorrhage, transcatheter arterial embolization (TAE) was the 
first intervention. If TAE failed, emergency laparotomy was 
performed. After the hemodynamic status was stabilized, the 
patients underwent complete clinical evaluation to formulate a 
definitive HCC treatment plan, including serology, Child-Pugh 
grading, abdominal CT, hepatic angiography, and measurement 
of indocyanine green retention at 15 minutes. The feasibility of 
hepatectomy was assessed based on the test results. In surgical 
candidates, elective hepatectomy was preformed, with the 
resection type decided based on the liver functional reserve and 
patient performance status [6]. In patients for whom surgery 
was not an option, TACE was performed 2–4 months after TAE. 
All patients were followed up at least every 3 months. Dynamic 
CT was performed at each follow-up appointment, and serum 
α-FP and DCP levels were screened. HCC recurrence was 
defined as newly developed lesions detected by CT. Patients 
with suspected recurrence underwent magnetic resonance 
imaging or hepatic angiography.
Analysis of prognosis and treatment outcome
We compared the survival curves of the patients that received 
staged hepatectomy or TACE alone to evaluate the impacts of 
the treatments on patient prognosis. To identify prognostic 
factors for patients with spontaneous ruptured HCC, we 
investigated the clinical characteristics at the time of diagnosis 
of tumor rupture using Cox-regression analysis. The analysis 
of postoperative complications employed the Clavien-Dindo 
classification [12]. Pleural effusion, ileus, and fluid accumulation 
in the operating field were radiologically diagnosed. Acute renal 
failure was defined as abrupt and reversible declines in renal 
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filtration function.
To compare treatment outcomes between staged hepatectomy 
and TACE alone in spontaneously ruptured HCC, we performed 
propensity score-matching to adjust for significant differences 
in patient characteristics. We excluded matching the patients 
with concomitant extrahepatic metastasis at diagnosis of 
HCC. Thus, we conducted propensity score-matching on the 
remaining 85 ruptured HCC patients who underwent TACE 
alone to select the matched group for staged hepatectomy 
group.
Statistical analysis
The propensity scores were estimated by multiple logistic 
regression analysis. Regression analysis predicted the 
probability that each patient would be treated based on 5 
covariables: age, hemoglobin, tumor size, multiple tumor, and 
Child-Pugh grade. Using these 5 covariables in the regression 
analysis, a propensity score was calculated for each patient. The 
discrimination and calibration abilities of the propensity score 
models were assessed with the C-statistic and the Hosmer- 
Lemeshow statistic [6]. The model was then used to obtain a 
one-to-one match for the staged hepatectomy group and TACE 
alone group. Finally, each patient with staged hepatectomy 
was matched to one patient with TACE alone, and the identical 
propensity score. After the propensity score-matched sample 
was formed, we assessed baseline variable balance between 
the 2 propensity-matched cohort groups. Continuous variables 
were compared with the paired t-test or the Wilcoxon signed 
rank test, as appropriate, and categorical variables were 
compared with the McNemar’s or marginal homogeneity test, 
as appropriate [13]. Propensity score-matching were performed 
with SAS ver. 9.2 (SAS Institute Inc, Cary, NC, USA).
Data are presented as the number of patients (percentage) or 
as the median value (range). We analyzed categorical variables 
using the chi-square test or Fisher exact test and continuous 
variables using the Mann-Whitney U-test. We calculated 
overall survival (OS) rates using the Kaplan-Meier method and 
evaluated differences in survival between groups using the log-
rank test. We calculated OS as the time from treatment until 
death from any cause, or until the end of follow-up. Variables 
found to be significant prognostic factors by univariate analysis 
were considered in a multivariate analysis. We considered 
P-values <0.05 statistically significant. Statistical procedures 
were conducted with the IBM SPSS ver. 18.0 (IBM Co., Armonk, 
NY, USA).
RESULTS
Patient characteristics
A total of 172 patients with newly diagnosed ruptured 
HCC were treated in 6 Korean centers. The median follow-
up duration among all patients was 5 months (range, 0–162 
months). The most frequently performed treatment was TACE 
(52.3%), followed by surgery (28.5%) and supportive care (13.4%) 
(Table 1). Chemotherapy and radiotherapy were each performed 
in 5 of patients (2.9%). The patients were managed according 
to the flow chart in Fig. 1. Eight patients had concomitant 
extrahepatic metastasis, and 117 patients had Child-Pugh 
class A disease. Among the 117 patients initially treated 
with TAE for hemostasis, 49 underwent surgery, 61 received 
TACE alone, and 7 received conservative treatment after TAE. 
Among the 49 patients that underwent surgery, 44 underwent 
staged hepatectomy after TAE, and 5 underwent emergency 
laparotomy due to hemostasis failure after TAE (bleeder ligation 
in 4 patients, tumor enucleation in 1 patient).
Among the 44 patients that underwent staged hepatectomy, 
22 underwent major hepatectomy (11 right hepatectomy, 7 
left hepatectomy, 2 left extended hepatectomy, and 2 central 
bisectionectomy) and 22 underwent minor hepatectomy (6 
lateral sectionectomy, 1 anterior sectionectomy, 1 posterior 
sectionectomy, 8 segmentectomy, and 6 wedge resection). The 
median time between TAE and staged hepatectomy was 16 
days (range, 7–375 days).
The patient characteristics at the time of HCC rupture 
diagnosis are summarized in Table 2. Compared with the 
patients that received staged hepatectomy, the patients that 
Hyung Soon Lee, et al: Staged hepatectomy vs. TACE for ruptured HCC
Table 1. Patient numbers according to the treatment modality and center
Center Total, n (%) Surgery TACE Supportive care
Chemo-
therapy
Radio-
therapy
Severance Hospital 60 (34.9) 27 31 2 0 0
Gangnam Severance Hospital 25 (14.5) 6 11 3 2 3
Wonju Severance Christian Hospital 32 (18.6) 7 17 7 1 0
CHA Medical Center 15 (8.7) 2 12 1 0 0
National Health Insurance Service Ilsan Hospital 20 (11.6) 2 8 10 0 0
Ajou University Medical Center 20 (11.6) 5 11 0 2 2
Total 172 (100) 49 (28.5) 90 (52.3) 23 (13.4) 5 (2.9) 5 (2.9)
TACE, transarterial chemoembolization.
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received TACE alone had significantly lower hemoglobin levels 
and significantly greater age, tumor size, frequency of multiple 
tumors, and total bilirubin levels.
Staged hepatectomy complications
Seventeen patients that underwent staged hepatectomy 
(16.2%) experienced complications. Grade I complications 
developed in nine patients (4 superficial surgical wound 
infection and 5 pleural effusion) and were managed conserva-
tively. Grade II complications developed in eight patients (5 fluid 
accumulation at the resected liver surface, 2 postoperative ileus, 
and 1 acute renal failure). The patients with fluid accumulation 
were successfully treated with antibiotic optimization. The 
patients with ileus successfully recovered after nasogastric tube 
placement. The patient with renal failure received intermittent 
diuretic therapy and recovered normal renal filtration rates. 
There were no complications above type IIIa.
Comparison of OS between staged hepatectomy 
and TACE alone 
The 1-, 3-, and 5-year OS rates were respectively 40.1%, 
15.7%, and 10.5% in the patients that underwent TACE alone 
172 Spontaneous rupture of HCC
37 Child-Pugh B (22.6%)
20 TACE 17 Conservative
a)
8 Concomitant extrahepatic
metastasis
10 Child-Pugh C (6.1%)
4 TACE 6 Conservative
a)
117 Child-Pugh A (71.3%)
49 Surgery 61 TACE 7 Conservative
a)
5 Bleeder ligation44 Staged hepatectomy
Fig. 1. Patient selection schematic. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization. a)Supportive care, 
radiotherapy and chemotherapy.
Table 2. Patient characteristics at the time of diagnosis of tumor rupture
Characteristic Staged hepatectomy (n = 44) TACE alone (n = 61) P-value
Age (yr) 51.5 (18–80) 61 (32–79) 0.009
Male sex 34 (77.3) 52 (85.2) 0.295
HBV surface antigen (+) 36 (81.8) 42 (68.9) 0.495
Shock on presentation 13 (29.5) 24 (39.3) 0.300
Portal vein thrombosis 4 (9.1) 12 (19.7) 0.137
Tumor size (cm) 6.7 (2.2–15.0) 8.4 (2.9–20.0) 0.012
Multiple tumor  5 (11.4) 26 (42.6) 0.001
Pretreatment transfusion 21 (47.7) 37 (60.7) 0.189
Pretreatment transfusion > 1,200 (mL) 12 (27.3) 24 (39.3) 0.199
α-FP (ng/mL) 144.5 (1.1–83,000) 62 (1.8–200,000) 0.082
Des-gamma-carboxy prothrombin (AU/mL) 806.5 (13.0–23,641) 2,000 (20.0–69,660) 0.249
Hemoglobin (g/dL) 11.6 (8.0–16.2) 10.7 (5.5–15.9) 0.045
Platelet (103/µL) 184 (69–467) 165 (65–454) 0.138
Creatinine (mg/dL) 0.8 (0.3–3.0) 1.0 (0.5–4.1) 0.419
Aspartate aminotransferase (IU/L) 52 (12–386) 67 (20–466) 0.061
Alanine aminotransferase (IU/L) 45.5 (7–136) 43 (11–288) 0.084
Total bilirubin (mg/dL) 0.75 (0.2–1.7) 0.9 (0.2–2.8) 0.006
International normalized ratio 1.06 (0.34–1.61) 1.13 (0.84–1.77) 0.078
Values are presented as median (range) or number (%).
TACE, transarterial chemoembolization. 
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and 88.7%, 58.4%, and 43.8% in those that underwent staged 
hepatectomy (Fig. 2). The patients that underwent staged 
hepatectomy had significantly greater OS than those that 
underwent TACE alone (P < 0.001).
Comparison of OS between staged hepatectomy 
and TACE alone after propensity score matching
The 2 groups showed significant differences in age, tumor 
size, multiple tumor and Child-Pugh grading, before matching 
(Table 3). These differences between groups were eliminated 
after matching. After matching, 1-, 3-, and 5-year OS rates were, 
respectively, 47.7%, 27.3%, and 27.3% in the TACE-alone group 
and 83.3%, 75.0%, and 45.0% in the staged hepatectomy group 
(Fig. 2). After matching, staged hepatectomy group also had 
significantly greater OS than those that underwent TACE alone 
group (P = 0.006).
Prognostic factors for OS
In the univariate analysis, portal vein thrombosis, type of 
treatment, pretreatment transfusion >1,200 mL, serum α-FP 
level, tumor size >5 cm, and multiple tumors were significantly 
associated with OS (Table 4). In the multivariate analysis, type 
of treatment, presence of portal vein thrombosis, pretreatment 
transfusion >1,200 mL, and tumor size >5 cm were associated 
with poor OS.
Recurrence pattern after staged hepatectomy
HCC recurrence developed in 31 patients that underwent 
staged hepatectomy (70.5%). Common sites of HCC recurrence 
after staged hepatectomy were the liver (n = 16; 51.6%), lung 
(n = 7; 22.6%), peritoneum (n = 4; 12.9%), lymph nodes (n = 2; 
6.5%), adrenal gland (n = 1; 3.2%), and spleen (n = 1; 3.2%).
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Fig. 2. Comparison of overall survival between staged hepatectomy and TACE alone before matching (A) and after propensity 
score-matching (B). TACE, transarterial chemoembolization.
Table 3. Before and after propensity score matching of baseline variables in the staged hepatectomy group versus the TACE 
alone group
Variable
Before matching After matching
Staged hepatectomy 
(n = 44)
TACE alone 
(n = 85) P-value
Staged hepatectomy 
(n = 16)
TACE alone  
(n = 16) P-value
Age (yr) 53.43 ± 12.70 59.63 ± 12.07 0.008 57.38 ± 13.64 57.38 ± 14.66 >0.999
Hemoglobin (g/dL) 11.01 ± 2.16 10.55 ± 2.27 0.262 11.44 ± 1.97 11.35 ± 1.73 0.902
Tumor size (cm) 6.98 ± 3.23 9.25 ± 4.51 0.001 7.82 ± 3.42 7.83 ± 2.63 0.994
Multiple tumor 5 (11.4) 38 (44.7) <0.001 2 (12.5) 2 (12.5) >0.999
Child-Pugh grade
    A 44 (100) 61 (71.8) <0.001 16 (100) 16 (100) >0.999
    B 0 (0) 20 (23.5) 0 (0) 0 (0)
    C 0 (0) 4 (4.7) 0 (0) 0 (0)
Values are presented as mean ± standard deviation or number (%). 
TACE, transarterial chemoembolization. 
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DISCUSSION
Staged hepatectomy resulted in better long-term survival 
than TACE alone in patients with HCC with recent tumor 
rupture. There were no complications above type IIIa after 
staged hepatectomy. Multivariate Cox-regression analysis 
showed that the type of treatment, pretreatment transfusion 
>1,200 mL, presence of portal vein thrombosis, and tumor size 
>5 cm were associated with poor prognosis in patients with 
spontaneous ruptured HCC. Those results suggest that the type 
of treatment may be an important factor for long-term survival 
in patients with ruptured HCC.
The treatment of spontaneous ruptured HCC remains 
a complicated issue, because patients often present with 
an advanced tumor stage and poor liver function. There is 
insufficient time to evaluate precise liver functional reserve 
and tumor status in such patients, because hemorrhage 
from ruptured HCC leads to coagulopathy and hemodynamic 
instability. Therefore, hemostasis is the primary purpose of 
initial treatment. Emergency hepatectomy has the advantage of 
achieving both hemostasis and definitive treatment in a single 
operation; however, it may be associated with high morbidity 
and mortality [14,15]. TAE is reported to be a highly effective 
first-line approach to achieving hemostasis during the acute 
Table 4. Cox-regression analysis of prognostic factors for overall survival
Variable
Overall survival
HR 95% CI P-value
Univariate analyses
Age, 1-yr increase 1.940 0.994–1.035 0.164
Male sex 0.008 0.516–1.829 0.929
HBV surface antigen positivity 1.095 0.367–1.356 0.295
    No vs. yes
Shock on presentation 0.140 0.531–1.537 0.708
    No vs. yes
Portal vein thrombosis 13.333 0.155–0.570 <0.001
    No vs. yes
Type of treatment 26.205 0.106–0.367 <0.001
    Staged hepatectomy vs. TACE alone
Treatment institution 0.391 0.901–1.223 0.532
Pretreatment transfusion > 1,200 mL 5.005 0.319–0.927 0.025
    No vs. yes
Hemoglobin (g/dL) 1.271 0.821–1.055 0.260
Creatinine (mg/dL) 2.109 0.371–1.159 0.146
Albumin (g/dL) 0.776 0.483–1.318 0.378
Aspartate aminotransferase (IU/L) 2.225 0.999–1.005 0.136
Alanine aminotransferase (IU/L) 0.697 0.997–1.007 0.404
Platelet (103/µL) 0.006 0.997–1.003 0.940
Total bilirubin, mg/dL 3.598 0.986–2.402 0.058
International normalized ratio 0.173 0.352–4.993 0.678
α-FP (ng/mL) 5.162 1.000–1.000 0.023
Des-gamma-carboxy prothrombin (mAU/mL) 0.415 1.000–1.000 0.519
Tumor size > 5 cm 9.154 0.160–0.676 0.002
    No vs. yes
Multiple tumor 8.633 1.293–3.618 0.003
    Solitary vs. multiple
Multivariate analysis
Type of treatment 17.027 0.126–0.478 <0.001
    Staged hepatectomy vs. TACE alone
Pre-treatment transfusion > 1,200 mL 4.135 0.301–0.978 0.042
    No vs. yes
Portal vein thrombosis 10.485 0.143–0.620 0.001
    No vs. yes
Tumor size > 5 cm 4.183 0.196–0.966 0.041
    No vs. yes
HR, hazard ratio; CI, confidence interval; TACE, Transarterial chemoembolization.
 Annals of Surgical Treatment and Research 281
phase of ruptured HCC, with the most recent reports citing 
a hemostasis success rate >90% [8,9,16]. Additionally, TAE 
allowed time to complete preoperative clinical evaluation of the 
tumor and liver functional status by successfully controlling 
bleeding, which facilitated selection of surgical candidates 
among patients with ruptured HCC. In the current study, there 
were no complications above type IIIa after staged hepatectomy. 
With regard to the low complication rates in our study, the 
full preoperative clinical evaluations after hemodynamic 
stabilization may contribute to low morbidity and mortality 
[6]. Thus, TAE facilitates full preoperative clinical evaluation, 
thereby allowing safe surgery in patients with ruptured HCC.
Because ruptured tumors are considered to be T4, many 
institutions tend to exclude curative treatment for spontaneous 
HCC rupture [2,5,10,17]. In the current staging paradigm, HCC 
rupture is classified as T4 disease regardless of other tumor 
characteristics. That classification has been questioned in some 
previous studies, which suggested that classifying all ruptured 
HCCs as T4 may not accurately reflect the true prognosis [2,3]. 
Our previous report also demonstrated that most resectable 
ruptured HCCs are small or medium-sized solitary tumors, and 
there were no T4 tumors among the ruptured HCCs treated 
with staged hepatectomy when the factor of tumor rupture was 
excluded from the classification [6]. Thus, ruptured HCC should 
not be considered a “singular clinical entity” with the rupture 
event as the sole driving prognostic factor [18].
To date, the largest clinical experience of ruptured HCC was 
reported by Aoki et al. [2] from a nationwide survey in Japan 
that evaluated 1,160 patients treated in 800 centers across the 
country with a 5-year OS rate of 13.3%. In that study, an analysis 
of OS stratified according to the main treatment modality 
showed that the 1-, 3-, and 5-year OS rates after hepatic 
resection were 76.0%, 48.6%, and 33.9%, respectively, and the 1-, 
3-, and 5-year OS rates after TACE were 39.7%, 14.1%, and 6.0%, 
respectively. A recent systematic review showed that when OS 
was stratified by treatment modality, TACE was associated with 
worse 1-year and 3-year OS (37.3% and 17.3%, respectively) than 
staged hepatectomy (75.7% and 43%, respectively) [18]. Those 
findings are consistent with our observations that patients 
that underwent TACE alone had significantly lower OS rates 
than those that underwent staged hepatectomy. Our results 
also suggest that, in selected cases, long-term survival can be 
expected if the patient’s condition is tolerable regarding the 
curative treatment. Consequently, in patients with preserved 
liver function and resectable tumors, staged hepatectomy 
should be considered as a potential approach for achieving 
tumor control and long-term survival. TACE may be best 
employed in patients that are ineligible for surgery because of 
poor performance status, advanced underlying hepatic disease, 
or other comorbidities.
Previous studies provided data on prognostic factors associ-
ated with OS in patients with ruptured HCC. Several factors 
were associated with worse prognosis, including tumor size 
>10 cm, T4 ruptured HCC, presence of cirrhosis, higher Child-
Pugh class, lower hemoglobin, higher creatinine, higher α-FP, 
higher total bilirubin, portal vein invasion, protrusion >30% 
from the liver surface, and shock at diagnosis [18]. Those 
findings are consistent with our results regarding prognostic 
factors associated with OS following HCC rupture; however, 
the finding that pretreatment transfusion >1,200 mL is a 
prognostic factor is unique to our study. The association 
between allogenic blood transfusion and clinical outcomes 
for patients with HCC remains controversial [19,20]. Kwon et 
al. [21] demonstrated that allogenic blood transfusion has no 
influence on the long-term oncological outcome in HCC. Kuroda 
et al. [22] reported that perioperative blood transfusion did not 
influence the overall and disease-free survival rates in patients 
with HCC that underwent curative resection. However, a recent 
meta-analysis demonstrated that allogenic blood transfusion 
has a significantly deleterious effect on clinical outcomes and 
postoperative complications in patients with HCC [20]. Our 
results demonstrated that pretreatment transfusion >1,200 
mL had a negative effect on OS in patients with ruptured HCC. 
In that regard, there is a need to minimize blood loss during 
the management of patients with spontaneous ruptured HCC, 
and meticulous bleeding control is essential during staged 
hepatectomy.
This study has several limitations. Although it included 
multiple centers, it included only a small number of patients. 
Furthermore, the study was designed retrospectively, so 
selection bias is possible. And most of the patients had HBV-
related HCC, which is not the case in patient populations in 
Western countries [23].
In summary, our results indicate that staged partial 
hepatectomy may offer better long-term survival than TACE 
alone for patients with HCC with recent tumor rupture. Staged 
hepatectomy should be considered in cases of spontaneous HCC 
rupture with resectable tumor and preserved liver function. 
More specifically, staged hepatectomy should be considered 
in cases of absence of portal vein thrombosis, pretreatment 
transfusion ≤1,200 mL, and tumor size ≤5 cm. Furthermore, 
rupture itself may not be a prognostic factor for unfavorable 
surgical outcomes. Further clinical studies to determine the 
true impact of HCC rupture with regard to long-term prognosis 
are required in the form of prospective randomized trials with 
adequate sample sizes and prolonged follow-up.
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